Updating Our Understanding of Pulmonary Disease Associated With HIV Infection

Estébanez-Muñoz, Miriam; Soto-Abánades, Clara I.; Ríos-Blanco, Juan José; Arribas, José Ramón

doi:10.1016/j.arbr.2012.02.002

Cited by 7 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, the FEV 1 /FVC ratio (%) was higher in the matched IPAH/FPAH population. Exercise capacity was affected in both PAH groups according to reference values in healthy populations (571± 90 m) [29]. The lack of difference between the two groups persisted after age and sex matching.…”

Section: Discussionmentioning

confidence: 99%

Management and prognosis of HIV‐associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry

et al. 2022

View full text Add to dashboard Cite

Background. Pulmonary arterial hypertension (PAH) is an independent predictor of death in patients with human immunodeficiency virus (HIV) infection. HIV is the leading cause of PAH (HIV-PAH) worldwide.Aims. We described the characteristics, treatment patterns, and prognosis of a cohort of HIV-PAH patients and compared them with those of an equivalent cohort of patients with idiopathic/familial PAH (IPAH/FPAH).Methods. We retrospectively analysed and compared the demographic, clinical, and treatment data from patients with HIV-PAH and those with IPAH/FPAH in the Spanish PAH registry (REHAP) from 1998 to 2018. The HIV-PAH overall survival (OS) rate up to 5 years was compared to the age-and sex-matched IPAH/FPAH population. Changes in treatment patterns in patients with HIV-PAH after 2010 and their effects on OS were also analysed.Results. Compared to those with IPAH/FPAH (n = 739), patients with HIV-PAH (n = 132) were younger, mainly men, and had a better functional status. The clinical presentation, haemodynamics, and respiratory function were similar between the groups. Parenteral drug use was the most common mode of HIV transmission. Approximately 11% of patients with HIV-PAH did not receive PAH-targeted therapy. The age-and sex-adjusted 5-year OS rate from diagnosis was 74.0% for patients with HIV-PAH and 68.7% for those with IPAH (p < 0.159). During/after 2010, 23% of patients with IPAH/FPAH received upfront dual oral combination, while oral monotherapy remained the main first-line treatment in patients with HIV-PAH. The overall OS rate remained stable. Conclusions.Patients with HIV-PAH were predominantly young men. The short-term prognosis is similar to that of age-and sex-matched patients with IPAH/FPAH, despite a better functional status. Oral monotherapy remains the preferred firstline treatment in the current cohorts.

show abstract

Section: Discussionmentioning

confidence: 99%

Management and prognosis of HIV‐associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the mid-90s, with the introduction of new antiretroviral therapy (HAART), HIV patients have undergone a great change in their quality of life, with a decrease in morbidity and mortality [3] and a decrease of AIDS cases [4]. This has led to the emergence of non-infectious diseases in HIV patients that until now were more predominant in the general population, such as ischemic heart disease, oncological pathology, neurological diseases [5][6][7], etc. These non-infectious diseases were not previously diagnosed in the HIV patients, most probably, because these patients died before developing them.…”

Section: Introductionmentioning

confidence: 99%

Reason for HIV Patients Consultation to the Emergency Department in the HAART Era: Incidence and Mortality

Camón¹,

Perelló²,

Escoda³

et al. 2014

J AIDS Clin Res

View full text Add to dashboard Cite

The identification of patients was carried out by consulting, retrospectively, the medical records by doctors and nurses of ED staff, of the patients that flocked to ED, by any pathology, in appreciating the diagnosis and known HIV or diagnosed during their hospital admission. Patients referred from other hospitals that had previously been visited at their ED or consultations after the first visit were excluded. To assign the reason of consultation, the medical record was

show abstract

Hipertensión arterial pulmonar asociada a virus de la inmunodeficiencia humana. El tópico olvidado

Sandoval-Gutiérrez¹

2014

Archivos de Cardiología de México

View full text Add to dashboard Cite

Updating Our Understanding of Pulmonary Disease Associated With HIV Infection

Cited by 7 publications

References 80 publications

Management and prognosis of HIV‐associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry

Management and prognosis of HIV‐associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry

Reason for HIV Patients Consultation to the Emergency Department in the HAART Era: Incidence and Mortality

Hipertensión arterial pulmonar asociada a virus de la inmunodeficiencia humana. El tópico olvidado

Contact Info

Product

Resources

About